HDAC9 and colorectal carcinoma: Notably, a recent study showed that co-inhibition of JAK and HDAC, in combination with regorafenib, increased acetylation of H3K9, H4K8, and α-tubulin, resulting in enhanced apoptosis, cell cycle arrest, and immune infiltration in CRC, demonstrating the translational relevance of PTM-targeted combinatorial approaches [130].